What is ABECMA? ABECMA (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least four kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

ABECMA® harnesses
the power of CAR T cell therapy

Not an actual patient.

ABECMA was studied in adults with RRMM

In the ABECMA clinical trial:
  • All patients had received at least 3 other kinds of treatment that had not worked or had stopped working—
    including an IMiD® agent, a proteasome inhibitor, and an anti-CD38 antibody
  • 100 adults with RRMM were treated with ABECMA
    • 88 of the 100 patients had received 4 or more prior treatment regimens
  • Results were assessed at least 1 and 2 years after their infusion

Most adults in the clinical trial responded to ABECMA

ABECMA® Response Rates Graphic ABECMA® Response Rates Graphic
The median follow-up time was 27.3 months (the range was 24.1 to 33.1 months). Results were similar with a median of 13.2 months follow-up time (overall response: 72% [72 out of 100 patients]; complete response or better 28% [28 out of 100 patients]).

The most common side effects of ABECMA are fatigue, fever (100.4°F/38°C or higher), chills/shivering, severe nausea or diarrhea, decreased appetite, headache, dizziness/lightheadedness, confusion, difficulty speaking or slurred speech, cough, difficulty breathing, and fast or irregular heartbeat.

These are results experienced by people in the ABECMA clinical trial. Your results may be different.
Refer to our Glossary for additional multiple myeloma and CAR T cell therapy terms.

Rapid responses with a one-time infusion of ABECMA

83% of patients who responded to ABECMA responded within one month of their infusion (60 out of 72 patients; the range was 0.5 to 2.9 months).

ABECMA responses were

ABECMA® Duration of Response ABECMA® Duration of Response
Results were similar with a median of 10.7 months follow-up time (median duration of response: 11.0 months [72 out of 100 patients]; median duration of response for patients who achieved a complete response or better: 19.0 months [28 out of 100 patients]).
These are results experienced by people in the ABECMA clinical trial. Your results may be different.

Focus on your freedom after receiving ABECMA

While regular check-ins with your healthcare team are still required, the following are NOT required for your MM while responding to ABECMA:

Repeated infusions

Maintenance therapy

Daily pills

Duration of response is the
length of time a patient
continues to respond to therapy
without their multiple myeloma
growing or spreading.

The median is the middle
number in a set of data. This
means half the numbers in the
group are more than the median
and half the numbers in a group
are less than the median.

CAR=chimeric antigen receptor; RRMM=relapsed or refractory multiple myeloma.